<?xml version="1.0" encoding="UTF-8"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-10-29T21:50:09Z</responseDate><request verb="GetRecord" identifier="oai:munzur-rdlopen.rawdatalibrary.net:munzur/2753" metadataPrefix="oai_dc">https://munzur-rdlopen.rawdatalibrary.net/oai/request</request><GetRecord><record><header><identifier>oai:munzur-rdlopen.rawdatalibrary.net:munzur/2753</identifier><datestamp>2026-10-28T15:30:02Z</datestamp><setSpec>openaire</setSpec><setSpec>driver</setSpec><setSpec>com_munzur_1</setSpec><setSpec>col_munzur_2</setSpec><setSpec>com_munzur_11</setSpec><setSpec>col_munzur_164</setSpec></header><metadata><oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd"><dc:title>Lycopene ameliorates propionic acid-induced autism spectrum disorders by inhibiting inflammation and oxidative stress in rats</dc:title><dc:creator>Erten, Fusun</dc:creator><dc:subject>antioxidant</dc:subject><dc:subject>autism</dc:subject><dc:subject>behavioral disorders</dc:subject><dc:subject>lycopene</dc:subject><dc:subject>propionic acid</dc:subject><dc:subject>rats</dc:subject><dc:description>This study was conducted to study lycopene efficacy in brain-behavior, pro-inflammatory and apoptotic markers, and antioxidant levels in a rodent model. Rats were administered with propionic acid (PPA) (500 mg/kg BW) to induce autism-like disorders, then treated with different lycopene (L) concentrations (5, 10, 20 mg kg−1 day−1) for 35 days. The groups were: (i);control, (ii);PPA, (iii);PPA + L5, (iv);PPA + L10, and (v);PPA + L20. In this study, serum and brain malondialdehyde (MDA) levels decreased with lycopene supplements compared to the PPA group, similarly to the brain levels of inflammatory factors (IL-1α, IL-8, NF-κB, TNF-α; p &lt;.05). Besides, brain levels of anti-apoptotic Bcl-2 decreased, whereas pro-apoptotic Bax, antioxidant Nrf2, and HO-1 levels in brain increased compared with PPA (p &lt;.05). This study showed that lycopene might have therapeutic value to improve the dysfunctions in learning and memory in a dose-dependent way, along with the antioxidant, anti-inflammatory, and antiapoptotic molecular responses in a rat model of ASD-like disorders. Practical applications: This study suggested that lycopene can reduce propionic acid (PPA)-induced learning and memory impairment and oxidative damage by participating in multiple biological activities such as antioxidant, and anti-inflammatory effects. Lycopene protects serum and brain tissues against PPA induced oxidative damage in rats. These effects may be realized through up-regulation of the brain Nrf2/HO-1 pathway and down-regulation of the IL-1α, IL-8, TNF-α, and NF-κB levels. Lycopene may also contribute to memory and learning function, apoptotic/antiapoptotic modulation, and antioxidant and possible therapeutic efficacy in PPA-induced- Autism spectrum disorder cases.</dc:description><dc:publisher>John Wiley and Sons Inc</dc:publisher><dc:date>2021</dc:date><dc:type>Article</dc:type><dc:identifier>https://rdlopen.rawdatalibrary.net/r/munzur/2753</dc:identifier><dc:identifier>https://doi.org/10.1111/jfbc.13922</dc:identifier><dc:identifier>0145-8884</dc:identifier><dc:language>en</dc:language><dc:relation>Journal of Food Biochemistry</dc:relation><dc:rights>info:eu-repo/semantics/openAccess</dc:rights><dc:type>info:eu-repo/semantics/article</dc:type><dc:identifier>https://munzur-rdlopen.rawdatalibrary.net/tr/items/munzur/2753</dc:identifier></oai_dc:dc></metadata></record></GetRecord></OAI-PMH>